ASAS classification 2/3 readers | No SpA | Possible axSpA | Clinical arm only | MRI +mNY− | mNY+ |
---|---|---|---|---|---|
No. of patients | 69 | 89 | 53 | 51 | 22 |
Inflammatory lesions ≥1 | 25 | 29 | 19 | 27 | 12 |
% | 36.3 | 32.6 | 35.8 | 52.9 | 54.5 |
Inflammatory lesions ≥2 | 15 | 19 | 11 | 18 | 11 |
% | 21.7 | 21.3 | 20.8 | 35.3 | 50.0 |
Inflammatory lesions ≥3 | 11 | 10 | 6 | 12 | 9 |
% | 15.9 | 11.2 | 11.3 | 23.5 | 40.9 |
Inflammatory lesions ≥4 | 7 | 7 | 4 | 9 | 9 |
% | 10.1 | 7.9 | 7.5 | 17.6 | 40.9 |
Inflammatory lesions ≥5 | 2 | 4 | 2 | 7 | 6 |
% | 2.9 | 4.5 | 3.8 | 13.7 | 27.3 |
Fatty lesions ≥1 | 18 | 24 | 13 | 24 | 11 |
% | 26.1 | 27.0 | 24.5 | 47.1 | 50.0 |
Fatty lesions ≥2 | 11 | 16 | 8 | 17 | 9 |
% | 15.9 | 18.0 | 15.1 | 33.3 | 40.9 |
Fatty lesions ≥3 | 9 | 9 | 3 | 13 | 6 |
% | 13.0 | 10.1 | 5.7 | 25.5 | 27.3 |
Fatty lesions ≥4 | 6 | 7 | 2 | 11 | 4 |
% | 8.7 | 7.9 | 3.8 | 21.6 | 18.2 |
Fatty lesions ≥5 | 3 | 6 | 1 | 11 | 4 |
% | 4.3 | 6.7 | 1.9 | 21.6 | 18.2 |
Erosions ≥1 | 23 | 24 | 16 | 15 | 5 |
% | 33.3 | 27.0 | 30.2 | 29.4 | 22.7 |
Erosions ≥2 | 10 | 10 | 5 | 8 | 4 |
% | 14.5 | 11.2 | 9.4 | 15.7 | 18.2 |
Erosions ≥3 | 5 | 4 | 4 | 4 | 3 |
% | 7.2 | 4.5 | 7.5 | 7.8 | 13.6 |
Erosions ≥4 | 2 | 4 | 1 | 2 | 1 |
% | 2.9 | 4.5 | 1.9 | 3.9 | 4.5 |
Syndesmophytes ≥1 | 17 | 21 | 8 | 19 | 2 |
% | 24.6 | 23.6 | 15.1 | 37.3 | 9.1 |
Syndesmophytes ≥2 | 6 | 11 | 5 | 6 | 0 |
% | 8.7 | 12.4 | 9.4 | 11.8 | – |
Syndesmophytes ≥3 | 5 | 7 | 3 | 3 | 0 |
% | 7.2 | 7.9 | 5.7 | 5.9 | – |
Syndesmophytes ≥4 | 2 | 3 | 2 | 1 | 0 |
% | 2.9 | 3.4 | 3.8 | 2.0 | – |
False positives ≤10% in italic; false positives ≤5% in italic and bold.
ASAS, Assessment of Spondyloarthritis international Society; axSpA, axial spondyloarthritis; mNY, modified New York criteria; SpA, spondyloarthritis.